|Fastest Growing Market:||Asia-Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The Non-small Cell Lung Cancer (NSCLC) market is projected to register a CAGR of 9.5% during the forecast period (2022-2027).
Covid-19 significantly affected the non-small cell lung cancer-related clinical trials across the world. Several market players halted their clinical trials due to a financial crisis in the year. For instance, according to ClinicalTrails.gov, it was observed that more than 200 interventional studies were halted during the period of March to April 2020 due to the emergence of COVID-19. Additionally, fluctuation in the market is mainly due to the disruption in the supply chain of raw materials and end products.
The growing number of patients suffering from non-small cell lung cancer across the world is one of the key drivers of the growth of the market. This is majorly due to the increasing number of people with unhealthy habits such as smoking, tobacco & alcohol consumption, high dose of supplements, and sedentary lifestyle across the world. Additionally, increasing pollution level in the air is also one of the major factors contributing to the increase in the number of patients. As per the statistics provided by the World Health Organization (WHO), 2.2 million patients were diagnosed with lung cancer in 2020, and non-small cell lung cancer accounted for nearly 85% of the share of all lung cancer patients. Thus, the availability of a large patient base and a further increasing number of non-small cell lung cancer patients resulted in the high demand for therapy to treat the patients.
- Recent approvals of new drugs are expected to accelerate the market growth during the forecast period. In February 2022, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Genentech’s Tecentriq to treat early-stage non-small cell lung cancer. Similarly, in October 2021, the United States Food and Drug Administration (U.S. FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) in the U.S. for stage II and IIIA non-small cell lung cancer patients. In March 2021, the FDA approved Pfizer’s Lorbrena (lorlatinib) to treat ALK-positive NSCLC patients in the U.S. Additionally, in October 2021, Ventana Medical Systems, Inc. received the U.S. FDA approval for VENTANA PD-L1 (SP263) Assay as a companion diagnostic device to select patients for Tecentriq. Hence, recent new drug approvals and the launch of companion diagnostics to select targeted patients are responsible for the growth of the market during the forecast period.
Scope of the Report
As per the scope of this report, non-small cell lung cancer is a type of epithelial lung cancer, excluding small-cell lung carcinoma. The non-small cell lung cancer market is segmented by Cancer Type (Squamous Cell Carcinoma, Adenocarcinoma, Large-cell Carcinoma), By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America).
|By Cancer Type|
|Squamous Cell Carcinoma|
|Others (Surgery & Radiation Therapy)|
Key Market Trends
The Targeted Therapy Segment is Expected to Hold a Major Market Share in the Non-Small Cell Lung Cancer Market
Targeted therapy drugs are often used to treat advanced lung cancers and are either used along with chemotherapy or used individually. Some of the major targeted therapy drugs to treat non-small cell lung cancer are Erlotinib (Tarceva), Gefitinib (Iressa), Afatinib (Gilotrif), Mobocertinib (Exkivity), Osimertinib (Tagrisso), and Dacomitinib (Vizimpro). These drugs targets mutated genes in the body and thereby avoid adverse effect on healthy cells. Investment by market players for the development of targeted therapy due to its advantages over standard chemotherapy and entry of these drugs in multiple countries across the world are likely to drive the market growth.
- Major genes affected during non-small cell lung cancer are the KRAS gene, EGFR gene, T790M, ALK gene, ROS1, BRAF gene, RET, and MET gene. Hence, targeted therapy targets these genes, avoid their proliferation, and thereby helps to treat non-small cell lung cancer. Investment by industry players for R&D activities responsible for the development of new treatments to treat various mutations during non-small cell lung cancer. For instance, in May 2021, the U.S.FDA approved Rybrevant (amivantamab-vmjw) first-line treatment for a specific type of genetic mutated non-small cell lung cancer in adult patients. Rybrevant is the first targeted therapy for patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations in the United States. The same day FDA approved Guardant Health Inc.’s Guardant360 CDx, a companion diagnostic for Rybrevant. Hence, approval and launch of such targeted therapy and their companion diagnostics are expected to propel the market growth during the forecast period. A strong pipeline of targeted therapy for non-small cell lung cancer is also expected to boost the market during the forecast period.
To understand key trends, Download Sample Report
North America Held a Maximum Share in the Market and Expected to do Same in the Forecast Period
North America is contributing a higher share across the world, majorly due to the high contribution from the United States. This can be majorly due to the local presence of major industry players, well-established healthcare infrastructure, and high diagnosis and treatment rates in the country.
Furthermore, the rise in the geriatric population and the increasing prevalence and incidence of non-small cell lung cancer due to unhealthy lifestyles in this region are some of the other driving factors of the market. For instance, as per the statistics provided by the National Cancer Institute, about 236,740 new cases of lung cancer are expected to diagnose in the United States in 2022.
- Moreover, high research and development activities, the launch of companion diagnostics by industry players, and huge healthcare spending are fueling the growth of the overall regional market to a large extent. The cost of treatment which includes chemotherapy, immunotherapy, targeted therapy, radiation, and in some cases, surgery, is huge, and the availability of significant reimbursement in the region is likely to accelerate the market growth.
To understand geography trends, Download Sample Report
The non-small cell lung cancer market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. F. Hoffmann-La Roche, AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Bayer Healthcare, Eli Lilly and Company, and GlaxoSmithKline are some of the key companies dominating the global market.
In March 2022, Regeneron and BioNTech expanded their collaboration agreement for the development of Libtayo and FixVac (cemiplimab) Combination to treat advanced NSCLC.
November 2021, Galecto signed a clinical collaboration agreement with Roche for their Phase 2 trial of molecule in first-line non-small cell lung cancer.
- In April 2021, Sorrento Therapeutics, an oncology company, acquired Acea Therapeutics to expand its oncology portfolio. Also, Acea Therapeutics has multiple clinical and pre-clinical stage New Chemical Entity (NCE) to treat non-small cell lung cancer and B-cell lymphoma.
Table of Contents
1.1 Study Assumptions & Market Defination
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Investment by Market Players for the Development of New Therapy
4.2.2 Increasing Number of NSCLC Patients
4.3 Market Restraints
4.3.1 High Cost of Therapy/Drugs
4.3.2 Low Diagnosis Rate in Developing Countries
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Squamous Cell Carcinoma
5.1.3 Large-cell Carcinoma
5.2 By Treatment
5.2.2 Targeted Therapy
5.2.4 Others (Surgery & Radiation Therapy)
5.3.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East and Africa
5.3.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche Ltd.
6.1.3 Bristol-Myers Squibb Company
6.1.4 Merck & Co., Inc.
6.1.5 Novartis AG
6.1.6 Pfizer Inc.
6.1.7 Takeda Pharmaceutical Company Limited
6.1.8 Bayer AG
6.1.9 Eli Lilly and Company
6.1.10 GlaxoSmithKline plc.
6.1.12 Agennix AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Non-Small Cell Lung Cancer (NSCLC) Market market is studied from 2019 - 2027.
What is the growth rate of Global Non-Small Cell Lung Cancer (NSCLC) Market ?
The Global Non-Small Cell Lung Cancer (NSCLC) Market is growing at a CAGR of 9.5% over the next 5 years.
Which region has highest growth rate in Global Non-Small Cell Lung Cancer (NSCLC) Market ?
Asia-Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Non-Small Cell Lung Cancer (NSCLC) Market ?
North America holds highest share in 2021.
Who are the key players in Global Non-Small Cell Lung Cancer (NSCLC) Market ?
F. Hoffmann-La Roche Ltd. , Bristol-Myers Squibb Company, Pfizer Inc. , AstraZeneca, Novartis AG are the major companies operating in Global Non-Small Cell Lung Cancer (NSCLC) Market .